Each 1 scoop (10 mg) serving contains: 1,3-Dimethylamylamine 10 mg.
Brand name products often contain multiple ingredients. To read detailed information about each ingredient, click on the link for the individual ingredient shown above.
This product contains 1,3-dimethylamylamine (DMAA), also known as methylhexanamine or geranium extract. There are serious safety concerns about DMAA. It is a stimulant that can potentially increase blood pressure and increase the risk of adverse cardiovascular events. DMAA-containing products have been linked to over 40 serious adverse event reports including adverse cardiovascular, metabolic, nervous system, and psychiatric events. Reports of death have also occurred (17660,17663,17904,17906,17907,17908,17958). In 2011, US Department of Defense (DoD) temporarily banned the sale of DMAA-containing supplements in military stores due to safety concerns. Sales of these products will be prohibited until the DoD investigates reports of potential serious adverse outcomes related to this product (17904,17909). On April 9, 2012, DMAA was also banned in New Zealand due to safety concerns (17960). Due to its stimulant effects, DMAA was added to the World Anti-Doping Agency's prohibited substances list for 2010. It is listed using the name methylhexaneamine on the prohibited list (17600).
Supplements that contain DMAA often list rose geranium oil, geranium oil, or geranium stems on the label. Some supplement manufacturers claim that this is because rose geranium oil contains a small amount of dimethylamylamine. However, this has not been verified by laboratory analysis. Some laboratories have not been able to detect dimethylamylamine in geranium oil. There is concern that some supplement manufacturers may be artificially spiking their supplements with this synthetic drug (17661,17662). In 2011, Health Canada determined that there is no credible evidence that DMAA is derived from the geranium plant. Therefore, DMAA is considered a drug and is not allowed in dietary supplements in Canada (17959).
For more information about DMAA, see the complete scientific monograph
Below is general information about the effectiveness of the known ingredients contained in the product 1,3 Dimethylamylamine Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
INSUFFICIENT RELIABLE EVIDENCE to RATE
Below is general information about the safety of the known ingredients contained in the product 1,3 Dimethylamylamine Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
LIKELY UNSAFE ...when used orally. 1,3-DMAA is a drug originally used as a stimulant nasal decongestant. There is concern that it increases the risk of serious adverse cardiovascular events, similar to other stimulants such as synephrine in bitter orange and ephedrine alkaloids from ephedra. There are several case reports linking 1,3-DMAA to serious adverse events including lactic acidosis, hemorrhagic stroke, heat stroke, and death (17599,17660,17662,17663,17904,94361,94369,94374). Although some supplement manufacturers claim that 1,3-DMAA is a natural compound found in geranium oil, this has not been verified by laboratory analysis. Some laboratories have not been able to detect 1,3-DMAA in geranium oil (94370,94372). There is concern that some supplement manufacturers may be artificially spiking their supplements with this synthetic drug (17661,17662). The New Zealand government restricted sales of supplements containing 1,3-DMAA to prevent the sale to people under 18 years of age due to concerns about safety (17599). The FDA has declared products containing 1,3-DMAA to be illegal and potential health risks (94383). Avoid using.
PREGNANCY AND LACTATION:
Insufficient reliable information available; avoid using.
Below is general information about the interactions of the known ingredients contained in the product 1,3 Dimethylamylamine Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
1,3-DMAA strongly inhibits cytochrome P450 2D6 (CYP2D6) enzymes in vitro (91878). Theoretically, 1,3-DMAA can increase levels of CYP2D6 substrates. Some of drugs that are CYP2D6 substrates include amitriptyline (Elavil), clozapine (Clozaril), codeine, desipramine (Norpramin), donepezil (Aricept), fentanyl (Duragesic), flecainide (Tambocor), fluoxetine (Prozac), meperidine (Demerol), methadone (Dolophine), metoprolol (Lopressor, Toprol XL), olanzapine (Zyprexa), ondansetron (Zofran), tramadol (Ultram), trazodone (Desyrel), and others.
|
1,3-DMAA is thought to have stimulant effects (94367). There is concern that taking 1,3-DMAA with stimulant drugs might increase the risk of adverse cardiovascular effects. Some preliminary research shows that taking 1,3-DMAA 50 mg daily in combination with caffeine 250 mg daily does not increase respiratory rate, blood pressure, or other cardiovascular outcomes compared to taking caffeine alone in healthy men (94364). However, a number of cardiovascular side effects have been reported for patients taking 1,3-DMAA in combination with other stimulants including caffeine (17660,91680,94362,94365,94371,94377). Theoretically, combining 1,3-DMAA with stimulant drugs might increase the risk of adverse cardiovascular effects. Some stimulant drugs include amphetamine, caffeine, diethylpropion (Tenuate), methylphenidate, phentermine (Ionamin), pseudoephedrine (Sudafed, others), and many others.
|
Below is general information about the adverse effects of the known ingredients contained in the product 1,3 Dimethylamylamine Powder. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.
General
...Orally, taking 1,3-DMAA combination products (OxyELITE Pro, AmphetaLean, or Jack3d, USPlabs) has been reported to cause cardiac arrest, atrial fibrillation, chest pressure, angina, tachycardia, palpitations, hypertension, hypotension, myocardial infarction, and acute coronary syndrome (17660,91680,94361,94362,94365,94369,94371,94377).
Increased heart rate and blood pressure have also been reported. Other reported adverse effects associated with the use of 1,3-DMAA-containing products have included life-threatening lactic acidosis (17660), nausea, vomiting, diarrhea, and abdominal pain (17663,17907,17908,94365,94371,94377), urinary changes (17663,94365,94371,94377), liver injury (94367,94368,94369), anaphylaxis (94365), muscle symptoms such as spasm or weakness (94377), neurological symptoms including tremors, insomnia, sweating, tiredness, confusion, headache, and chills (17907,17663), hemorrhagic stroke (17663,90318), pupil dilation or tinnitus (94365,94371), psychiatric symptoms such as anxiety, agitation, paranoia, and aggression (17660,17907,94365,94371,94377), or rapid breathing (17660,94371). The dose of 1,3-DMAA at which such adverse effects occur is not clear (94368).
Death has occurred in some cases following organ failure and cardiac arrest (17904,94361,94369,94374).
Topically, rubbing an eye while mixing a drink with a 1,3-DMAA-containing combination product (Jack3d) has caused pupil dilation (94368).
Cardiovascular
...Due to the stimulant effects of 1,3-DMAA, there is concern that it might increase the risk of adverse cardiovascular events similar to synephrine from bitter orange or ephedrine from ephedra.
Cardiovascular outcomes have rarely been assessed in patients taking 1,3-DMAA alone. Most adverse effects are linked to 1,3-DMAA-containing combination products. Palpitations and tachycardia are some of the most common side effects reported for adults and children taking 1,3-DMAA-containing combination products (17660,91680,94365,94371). Other less common adverse effects have included chest pressure, angina, atrial fibrillation, hypertension, hypotension, myocardial infarction, and acute coronary syndrome (17660,91680,94362,94365,94371,94377).
There is inconsistent data about the effects of 1,3-DMAA on heart rate and blood pressure (94368). For example, some research suggests that taking specific 1,3-DMAA-containing combination products (OxyELITE Pro or Jack3d, USPlabs) significantly increases systolic blood pressure and increases heart rate within 1-2 hours of taking a dose. These increases appear to be dose dependent (17906,17907,17908). However, in an 8-week study, heart rate was significantly increased, but blood pressure was not (17907). Other research shows that neither acute nor chronic intake of 1,3-DMAA increases heart rate or blood pressure (17908,94364,94368,94376). Overall, it seems that oral intake of a single dose of a 1,3-DMAA-containing product is more likely to increase systolic blood pressure. Resting blood pressure is less likely to remain increased following chronic use (94368,94379). Higher doses are more likely to increase heart rate and blood pressure. Although most sports supplements contain 25-65 mg/dose, some contain as much as 285 mg/dose (94377).
In case reports of healthy young adults taking 1,3-DMAA-containing combination products prior to exercise, cardiac arrest causing death has occurred (94361,94369).
Endocrine ...In one report, a patient who took a specific combination product containing 1,3-DMAA (Jack3d by USP Labs) prior to intense exercise experienced life-threatening lactic acidosis (17660).
Gastrointestinal ...Orally, taking 1,3-DMAA-containing combination products has been reported to cause nausea (17907,17908,94365,94371,94377), vomiting (17663,94365,94371,94377), diarrhea (94365), vomiting blood (94371), and abdominal pain (94371).
Genitourinary ...Urinary hesitancy (94365), urinary retention (94371), and uncontrolled urination (94377), have been reported following ingestion of 1,3-DMAA-containing combination products.
Hepatic ...Acute liver injury, in some cases requiring a liver transplant, has been reported following oral intake of 1,3-DMAA-containing products (94367,94368,94369).
Immunologic ...An anaphylactic reaction has been reported following oral intake of 1,3-DMAA-containing products (94365).
Musculoskeletal ...Orally, dimethylamine-containing products have caused muscle spasm (94365), muscle weakness (94377), and leg pains (94377).
Neurologic/CNS ...Orally, taking specific 1,3-DMAA-containing combination products (OxyELITE Pro or Jack3d, USPlabs) has been reported to cause feelings of jitters, sleeplessness, shakiness, chills, sweating, fatigue, tingling, and lack of focus in clinical trials (17907). Other adverse effects reported for products containing 1,3-DMAA have included headache, dizziness, tremor, numbness, flushing, seizure, blacking out, visual disturbances, confusion, and lethargy (17660,17908,94365,94368,94371,94377). In a case report, a 26 year old male reported with a hemorrhagic stroke linked to taking the supplement Jack3d, which contains 1,3-DMAA, schizandrol A, caffeine, beta-alanine, creatine, and L-arginine alpha-ketoglutarate (90318). In another report, a patient experienced a hemorrhagic stroke after taking two tablets of a product containing 1,3-DMAA 278 mg each along with caffeine 150 mg and a can of beer (17663).
Ocular/Otic ...Orally, dimethylamine-containing products have caused tinnitus (94365) and pupil dilation (94371). Pupil dilation also occurred after rubbing an eye while mixing a drink with the specific product Jack3d, containing 1,3-DMAA (94368).
Psychiatric ...Orally, taking 1,3-DMAA-containing combination products has been reported to cause feelings of anxiety (17907,94365), suicidal behavior (94365), agitation or irritability (94365,94371,94377), paranoia (94377), depression (94377), panic (94377), and aggression or combativeness (17660,94365).
Pulmonary/Respiratory ...Orally, combination products containing 1,3-DMAA have caused rapid breathing and hyperventilation (17660,94371).
Other ...There are at least two reports of death in US Army soldiers who took 1,3-DMAA supplements and suffered heat stroke and related complications following physical fitness training (17904).
